The DOI matches its Crossref record.
FROM THE FDA
Open accessAbstract
Deputy Center Director (Review Management), Center for Drug Evaluation and Research."Subject: Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture"Dear Health Care Professional:The Food and Drug Administration (FDA) would like to call to your attention recent postmarketing reports of patients who have developed epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. Many of the hematomas caused neurologic injury, including long-term or permanent paralysis. Because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. However, given the potential seriousness of this complication, we believe that patients and health care professionals should be notified of this information.The postmarketing reports received to date involved patients who were treated with Lovenox[registered sign](enoxaprin sodium) Injection. However, the adverse event would be expected to occur if drugs with similar pharmacological activity were used in the same manner. Therefore, the FDA has asked all manufacturers of low molecular weight heparins and heparinoids to revise their package inserts to provide further information for the safe and effective use of these drugs. Specifically, the manufacturers have been asked to include additional safety information and recommendations in a boxed warning in their package inserts.- As of November, 1997, there have been more than 30 spontaneous safety reports describing patients who have developed epidural or spinal hematomas with concurrent use of enoxaparin sodium and spinal/epidural anesthesia or spinal puncture. Many of the epidural or spinal hematomas caused neurologic injury, including long-term or permanent paralysis.- Approximately 75% of the patients were elderly women undergoing orthopedic surgery."At this time, the FDA believes practitioners should be aware of the following points if using these products:- When neuraxial anesthesia (epidural/spinal anesthesia) or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated wit low molecular weight heparins or heparinoids for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.- The risk of these events is increased by the use of indwelling epidural catheters for administration of analgesia or by the concomitant use of drugs affecting hemostasis such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet infibitors, or other anticoagulants. The risk also appears to be increased by traumatic or repeated epidural of spinal puncture.- Patients should be frequently monitored for signs and symptoms of neurological impairment. If neurologic compromise is noted, urgent treatment is necessary.- Practitioners should consider fully the potential benefit versus risk before neuraxial intervention in patients anticoagulated or to be anticogulated for thromboprophylaxis.The FDA will continue to monitor closely postmarketing reports for additional events. We encourage all health care professionals to report any serious adverse events, including cases of epidural or spinal hematomas, occurring with the use of low molecular weight heparins, heparinoids, or other anticoagulants to the FDA's MEDWATCH program at 1–800-FDA-1088/fax 1–800-FDA-0178; or to the respective pharmaceutical manufacturers:- Fragmin[registered sign](dalteparin sodium injection); Pharmacia & Upjohn; 1–800–253–8600, ext. 38244.- Lovenox[registered sign](enoxaparin sodium) Injection; Rhone-Poulenc Rorer Pharmaceuticals Inc.; 1–800–857–7497.- Normiflo[registered sign](ardeparin sodium) Injection; Wyeth Laboratories Inc.; 1–800–934–5556.- Orgaran[trademark symbol](danaparoid sodium) Injection; Organon Inc.; 1–800–631–1253.Murray M. Lumpkin, M.D.Deputy Center Director (Review Management); Center for Drug Evaluation and Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Guidelines for Prevention of NSAID-Related Ulcer Complications
and the Practice Parameters Committee of the American College of Gastroenterology, Lanza, F. L., Chan, F. K. L., & Quigley, E. M. M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.115 · Cited by 790
(2002) · PsycEXTRA Dataset · doi:10.1037/e548362006-001 · Cited by 517
Metadata
- Authors
- Lumpkin, M. M.
- Venue
- Anesthesiology
- Published
- 1998-02-01
- Volume
- 88
- Issue
- 2
- Pages
- 27A-28A
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2024857678
- Cited by
- 197
- References
- 0
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FROM THE FDA. https://app.cochat.ai/papers/10.1097/00000542-199802000-00001
- The paper
- Lumpkin, M. M. (1998). FROM THE FDA. Anesthesiology. https://doi.org/10.1097/00000542-199802000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.